By Brazil Stock Guide – Oncoclinicas (ONCO3) has delayed the release of its 2025 financial results from March 30 to April 9, a move that expands its room for maneuver at a critical juncture. Although the deadline for releasing results expires on March 31, the company gains additional days to align with creditors while negotiating a restructuring with Porto and Fleury — a process that could determine its survival.
At the center is a waiver request tied to a potential breach of the Net Debt/EBITDA covenant in 2025. The proposal will be voted on at a creditor meeting scheduled for April 2 at 11 a.m., with remote voting allowed until March 31. The waiver is conditional: it only becomes effective if the ratio exceeds 3.5x, signaling that the company is already working under a realistic assumption of a breach and is attempting to avoid a technical default that could trigger debt acceleration.
Liquidity remains the key pressure point. Even after a capital increase of up to R$2 billion, with limited cash inflow due to a significant portion being debt conversion, the company acknowledges it may not meet its financial commitments.
Oncoclinicas is also evaluating a potential R$500 million capital injection from MAK Capital, signaling external interest in its assets but underscoring the urgency of its short-term funding needs. Without the waiver, the immediate risk is a technical default, potentially leading to accelerated liabilities and a rapid deterioration in liquidity.
Restructuring in Play
The timeline now converges on four critical dates. On March 31, the deadline for releasing results and submitting remote votes expires. On April 2, creditors will decide on the waiver. On April 9, the company will publish its financial results. And on April 13, the 30-day exclusivity period granted to Porto and Fleury to negotiate a definitive agreement expires.
That agreement contemplates the creation of a new entity (NewCo), into which oncology clinics and up to R$2.5 billion in liabilities would be transferred, in exchange for R$500 million in equity and an additional R$500 million in convertible debentures. The transaction remains subject to due diligence, internal approvals and regulatory clearance.
Critical Window
The delay is more than procedural. By pushing the results release into April, the company buys time to negotiate with creditors and advance the transaction before financial statements formally confirm a covenant breach. The window, however, is narrow.
If the waiver is approved and negotiations with Porto and Fleury progress within the exclusivity period, the company may move toward an orderly restructuring. Otherwise, the risk shifts from technical to liquidity-driven — a scenario that could force more aggressive measures and potentially significant shareholder dilution.